Camrelizumab
- CAS No.
- 1798286-48-2
- Chemical Name:
- Camrelizumab
- Synonyms
- SHR-1210;Camrelizumab;Camrelizumab (anti-PD-1);Research Grade Camrelizumab;Research Grade Camrelizumab(DHH02211)
- CBNumber:
- CB28081005
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| storage temp. | 4°C, Do not freeze, Protect from light. |
|---|---|
| form | Solid |
| color | White to light yellow |
| FDA UNII | 73096E137E |
| NCI Drug Dictionary | camrelizumab |
Camrelizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0142321 | Camrelizumab 98.80% | 1798286-48-2 | 1mg | $217 | 2026-06-04 | Buy |
| ChemScene | CS-0142321 | Camrelizumab 98.80% | 1798286-48-2 | 5mg | $758 | 2026-06-04 | Buy |
| aablocks | AA01V7AN | Camrelizumab ≥95%(SDS-PAGE&SEC-HPLC) | 1798286-48-2 | 1mg | $340 | 2026-05-31 | Buy |
| aablocks | AA01V7AN | Camrelizumab ≥95%(SDS-PAGE&SEC-HPLC) | 1798286-48-2 | 5mg | $1134 | 2026-05-31 | Buy |
| Arctom | HY-P9971 | Camrelizumab 98.80% | 1798286-48-2 | 1mg | $190 | 2026-05-26 | Buy |
Camrelizumab Chemical Properties, Uses, Production
Uses
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumabbinds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts asanti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al[1][2].
in vivo
Camrelizumab (3 mg/kg) combines with apatinib (200 and 100 mg/kg) inhibits the tumor inhibition rates reached 63.1% and 87.3%, respectively in human PD-1 transgenic mice[1].
References
[1] Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191. DOI:10.1136/jitc-2020-002191
[2] Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther DOI:10.2147/DDDT.S243787
[3] Caicun Zho, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med.2021 Mar;9(3):305-314. DOI:10.1016/S2213-2600(20)30365-9
Camrelizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Camrelizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Kaifeng Mingren Pharmaceutical Co.,LTD | 0371-65741762 | sales@hasunny.com | China | 2377 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Shanghai Tachizaki Biomedical Research Center | 18014399201 | sales@chemlab-tachizaki.com | China | 2934 | 58 |
View Latest Price from Camrelizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-14 | Camrelizumab
1798286-48-2
|
$163.00-823.00 | 98.60% | 10g | TargetMol Chemicals Inc. |
-
- Camrelizumab
1798286-48-2
- $163.00-823.00
- 98.60%
- TargetMol Chemicals Inc.
